Drug Trial Radar · NCT04666688
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Dec 11, 2020
Primary completion
Dec 12, 2024
Study completion Dec 12, 2024
Sponsor
- Lead sponsor
- PureTechIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or tislelizumab in Patients with Metastatic Solid Tumors
Conditions
- Metastatic Cancer
- Solid Tumor
- Head and Neck Cancer
Interventions
LYT-200Drug
monoclonal antibody (mAb), targeting galectin-9 protein
TislelizumabDrug
anti-PD-1 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]Time frame: approximately 1 year
- Part 1: Incidence of Dose Limiting Toxicities [Tolerability]Time frame: approximately 1 year
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
University of Colorado Hospital
Denver, Colorado
Sarah Cannon Research Institute at Health One
Denver, Colorado
Sarah Cannon Research Institute, Florida Cancer Specialists
Sarasota, Florida
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
South Texas Accelerated Research Therapeutics
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Columbia University
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Sarah Cannon Research Institute, Tennessee Oncology
Nashville, Tennessee
University of Texas, M.D. Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.